Oncology Institute (TOI) Competitors

$4.98 -0.09 (-1.78%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$5.03 +0.04 (+0.90%)

As of 07/24/2026 07:34 PM Eastern

TOI vs. SGRY, AVAH, ADUS, AGL, and CDNA

Should you buy Oncology Institute stock or one of its competitors? MarketBeat compares Oncology Institute with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Oncology Institute include Surgery Partners (SGRY), Aveanna Healthcare (AVAH), Addus HomeCare (ADUS), Agilon Health (AGL), and CareDx (CDNA). These companies are all part of the "healthcare" industry.

How does Oncology Institute compare to Surgery Partners?

Surgery Partners (NASDAQ:SGRY) and Oncology Institute (NASDAQ:TOI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

Surgery Partners has a net margin of -2.28% compared to Oncology Institute's net margin of -7.42%. Surgery Partners' return on equity of 1.04% beat Oncology Institute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Surgery Partners	-2.28%	1.04%	0.41%
Oncology Institute	-7.42%	N/A	-24.68%

Surgery Partners currently has a consensus price target of $22.18, suggesting a potential upside of 41.02%. Oncology Institute has a consensus price target of $8.50, suggesting a potential upside of 70.68%. Given Oncology Institute's higher possible upside, analysts plainly believe Oncology Institute is more favorable than Surgery Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Surgery Partners	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.75
Oncology Institute	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, Surgery Partners had 6 more articles in the media than Oncology Institute. MarketBeat recorded 7 mentions for Surgery Partners and 1 mentions for Oncology Institute. Oncology Institute's average media sentiment score of 1.89 beat Surgery Partners' score of 0.66 indicating that Oncology Institute is being referred to more favorably in the news media.

Company	Overall Sentiment
Surgery Partners	Positive
Oncology Institute	Very Positive

Oncology Institute has lower revenue, but higher earnings than Surgery Partners. Surgery Partners is trading at a lower price-to-earnings ratio than Oncology Institute, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Surgery Partners	$3.31B	0.62	-$77.90M	-$0.60	N/A
Oncology Institute	$545.76M	0.90	-$60.61M	-$0.37	N/A

36.9% of Oncology Institute shares are held by institutional investors. 2.0% of Surgery Partners shares are held by company insiders. Comparatively, 4.4% of Oncology Institute shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Surgery Partners has a beta of 1.89, indicating that its stock price is 89% more volatile than the broader market. Comparatively, Oncology Institute has a beta of 0.36, indicating that its stock price is 64% less volatile than the broader market.

Summary

Surgery Partners beats Oncology Institute on 9 of the 17 factors compared between the two stocks.

How does Oncology Institute compare to Aveanna Healthcare?

Oncology Institute (NASDAQ:TOI) and Aveanna Healthcare (NASDAQ:AVAH) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends, media sentiment and valuation.

36.9% of Oncology Institute shares are owned by institutional investors. Comparatively, 88.0% of Aveanna Healthcare shares are owned by institutional investors. 4.4% of Oncology Institute shares are owned by company insiders. Comparatively, 5.3% of Aveanna Healthcare shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Oncology Institute currently has a consensus target price of $8.50, indicating a potential upside of 70.68%. Aveanna Healthcare has a consensus target price of $10.78, indicating a potential upside of 14.05%. Given Oncology Institute's higher probable upside, equities research analysts clearly believe Oncology Institute is more favorable than Aveanna Healthcare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncology Institute	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Aveanna Healthcare	0 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.67

Aveanna Healthcare has higher revenue and earnings than Oncology Institute. Oncology Institute is trading at a lower price-to-earnings ratio than Aveanna Healthcare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncology Institute	$545.76M	0.90	-$60.61M	-$0.37	N/A
Aveanna Healthcare	$2.52B	0.82	$225.03M	$1.18	8.01

In the previous week, Aveanna Healthcare had 4 more articles in the media than Oncology Institute. MarketBeat recorded 5 mentions for Aveanna Healthcare and 1 mentions for Oncology Institute. Oncology Institute's average media sentiment score of 1.89 beat Aveanna Healthcare's score of 1.03 indicating that Oncology Institute is being referred to more favorably in the media.

Company	Overall Sentiment
Oncology Institute	Very Positive
Aveanna Healthcare	Positive

Aveanna Healthcare has a net margin of 10.37% compared to Oncology Institute's net margin of -7.42%. Aveanna Healthcare's return on equity of 124.68% beat Oncology Institute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncology Institute	-7.42%	N/A	-24.68%
Aveanna Healthcare	10.37%	124.68%	7.07%

Oncology Institute has a beta of 0.36, indicating that its stock price is 64% less volatile than the broader market. Comparatively, Aveanna Healthcare has a beta of 1.89, indicating that its stock price is 89% more volatile than the broader market.

Summary

Aveanna Healthcare beats Oncology Institute on 14 of the 17 factors compared between the two stocks.

How does Oncology Institute compare to Addus HomeCare?

Oncology Institute (NASDAQ:TOI) and Addus HomeCare (NASDAQ:ADUS) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings and risk.

Oncology Institute has a beta of 0.36, suggesting that its share price is 64% less volatile than the broader market. Comparatively, Addus HomeCare has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market.

In the previous week, Addus HomeCare had 4 more articles in the media than Oncology Institute. MarketBeat recorded 5 mentions for Addus HomeCare and 1 mentions for Oncology Institute. Oncology Institute's average media sentiment score of 1.89 beat Addus HomeCare's score of 1.00 indicating that Oncology Institute is being referred to more favorably in the media.

Company	Overall Sentiment
Oncology Institute	Very Positive
Addus HomeCare	Positive

Oncology Institute presently has a consensus target price of $8.50, suggesting a potential upside of 70.68%. Addus HomeCare has a consensus target price of $131.50, suggesting a potential upside of 14.80%. Given Oncology Institute's higher possible upside, equities research analysts plainly believe Oncology Institute is more favorable than Addus HomeCare.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncology Institute	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Addus HomeCare	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.73

36.9% of Oncology Institute shares are held by institutional investors. Comparatively, 95.4% of Addus HomeCare shares are held by institutional investors. 4.4% of Oncology Institute shares are held by company insiders. Comparatively, 4.1% of Addus HomeCare shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Addus HomeCare has a net margin of 6.89% compared to Oncology Institute's net margin of -7.42%. Addus HomeCare's return on equity of 9.80% beat Oncology Institute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncology Institute	-7.42%	N/A	-24.68%
Addus HomeCare	6.89%	9.80%	7.34%

Addus HomeCare has higher revenue and earnings than Oncology Institute. Oncology Institute is trading at a lower price-to-earnings ratio than Addus HomeCare, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncology Institute	$545.76M	0.90	-$60.61M	-$0.37	N/A
Addus HomeCare	$1.42B	1.50	$95.91M	$5.41	21.17

Summary

Addus HomeCare beats Oncology Institute on 14 of the 17 factors compared between the two stocks.

How does Oncology Institute compare to Agilon Health?

Oncology Institute (NASDAQ:TOI) and Agilon Health (NYSE:AGL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

In the previous week, Agilon Health had 5 more articles in the media than Oncology Institute. MarketBeat recorded 6 mentions for Agilon Health and 1 mentions for Oncology Institute. Oncology Institute's average media sentiment score of 1.89 beat Agilon Health's score of 0.25 indicating that Oncology Institute is being referred to more favorably in the media.

Company	Overall Sentiment
Oncology Institute	Very Positive
Agilon Health	Neutral

Oncology Institute has a beta of 0.36, indicating that its share price is 64% less volatile than the broader market. Comparatively, Agilon Health has a beta of 2.98, indicating that its share price is 198% more volatile than the broader market.

Oncology Institute has higher earnings, but lower revenue than Agilon Health. Oncology Institute is trading at a lower price-to-earnings ratio than Agilon Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oncology Institute	$545.76M	0.90	-$60.61M	-$0.37	N/A
Agilon Health	$5.82B	0.28	-$391.35M	-$21.56	N/A

36.9% of Oncology Institute shares are held by institutional investors. 4.4% of Oncology Institute shares are held by company insiders. Comparatively, 2.5% of Agilon Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Agilon Health has a net margin of -6.09% compared to Oncology Institute's net margin of -7.42%. Oncology Institute's return on equity of 0.00% beat Agilon Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oncology Institute	-7.42%	N/A	-24.68%
Agilon Health	-6.09%	-146.03%	-24.55%

Oncology Institute presently has a consensus target price of $8.50, indicating a potential upside of 70.68%. Agilon Health has a consensus target price of $66.50, indicating a potential downside of 32.03%. Given Oncology Institute's stronger consensus rating and higher probable upside, research analysts clearly believe Oncology Institute is more favorable than Agilon Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oncology Institute	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
Agilon Health	3 Sell rating(s)	6 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.14

Summary

Oncology Institute beats Agilon Health on 9 of the 16 factors compared between the two stocks.

How does Oncology Institute compare to CareDx?

CareDx (NASDAQ:CDNA) and Oncology Institute (NASDAQ:TOI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, media sentiment, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.

CareDx has a beta of 2.43, meaning that its share price is 143% more volatile than the broader market. Comparatively, Oncology Institute has a beta of 0.36, meaning that its share price is 64% less volatile than the broader market.

CareDx currently has a consensus price target of $33.67, suggesting a potential downside of 9.35%. Oncology Institute has a consensus price target of $8.50, suggesting a potential upside of 70.68%. Given Oncology Institute's stronger consensus rating and higher probable upside, analysts clearly believe Oncology Institute is more favorable than CareDx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CareDx	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Oncology Institute	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

CareDx has higher earnings, but lower revenue than Oncology Institute. CareDx is trading at a lower price-to-earnings ratio than Oncology Institute, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CareDx	$379.80M	5.05	-$21.35M	-$0.16	N/A
Oncology Institute	$545.76M	0.90	-$60.61M	-$0.37	N/A

CareDx has a net margin of -2.01% compared to Oncology Institute's net margin of -7.42%. Oncology Institute's return on equity of 0.00% beat CareDx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CareDx	-2.01%	-2.65%	-1.96%
Oncology Institute	-7.42%	N/A	-24.68%

36.9% of Oncology Institute shares are held by institutional investors. 2.4% of CareDx shares are held by company insiders. Comparatively, 4.4% of Oncology Institute shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, CareDx had 6 more articles in the media than Oncology Institute. MarketBeat recorded 7 mentions for CareDx and 1 mentions for Oncology Institute. Oncology Institute's average media sentiment score of 1.89 beat CareDx's score of 1.08 indicating that Oncology Institute is being referred to more favorably in the news media.

Company	Overall Sentiment
CareDx	Positive
Oncology Institute	Very Positive

Summary

Oncology Institute beats CareDx on 9 of the 16 factors compared between the two stocks.

Get Oncology Institute News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TOI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TOI vs. The Competition

Export

Metric	Oncology Institute	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$492.22M	$9.51B	$6.87B	$12.26B
Dividend Yield	N/A	1.64%	2.67%	9.79%
P/E Ratio	-13.46	25.73	27.14	23.64
Price / Sales	0.90	26.20	517.08	89.50
Price / Cash	N/A	142.74	50.54	59.64
Price / Book	-31.13	6.11	10.28	6.07
Net Income	-$60.61M	$179.69M	$3.60B	$331.99M
7 Day Performance	-6.92%	-3.06%	-1.27%	-0.63%
1 Month Performance	-2.73%	0.49%	-0.37%	-2.00%
1 Year Performance	35.33%	9.52%	18.30%	13.62%

Oncology Institute Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TOI Oncology Institute	3.9841 of 5 stars	$4.98 -1.8%	$8.50 +70.7%	+36.4%	$492.22M	$545.76M	N/A	660	Positive News
SGRY Surgery Partners	3.4819 of 5 stars	$16.30 +1.7%	$22.18 +36.1%	-25.1%	$2.13B	$3.34B	N/A	16,000	News Coverage Gap Up
AVAH Aveanna Healthcare	4.6311 of 5 stars	$9.74 +0.5%	$10.78 +10.7%	+139.8%	$2.12B	$2.43B	8.25	35,500
ADUS Addus HomeCare	3.4258 of 5 stars	$113.31 +1.6%	$131.50 +16.1%	+5.9%	$2.11B	$1.45B	20.94	50,659	Analyst Forecast
AGL Agilon Health	0.9121 of 5 stars	$125.90 +3.1%	$64.00 -49.2%	+88.6%	$2.10B	$5.93B	N/A	1,076	News Coverage Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TOI) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oncology Institute (TOI) Competitors

TOI vs. SGRY, AVAH, ADUS, AGL, and CDNA

How does Oncology Institute compare to Surgery Partners?

Summary

How does Oncology Institute compare to Aveanna Healthcare?

Summary

How does Oncology Institute compare to Addus HomeCare?

Summary

How does Oncology Institute compare to Agilon Health?

Summary

How does Oncology Institute compare to CareDx?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TOI vs. The Competition

Oncology Institute Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oncology Institute (TOI) Competitors

TOI vs. SGRY, AVAH, ADUS, AGL, and CDNA

How does Oncology Institute compare to Surgery Partners?

Is SGRY or TOI more profitable?

Do analysts recommend SGRY or TOI?

Does the media refer more to SGRY or TOI?

Which has preferable earnings and valuation, SGRY or TOI?

Do institutionals and insiders believe in SGRY or TOI?

Which has more risk and volatility, SGRY or TOI?

Summary

How does Oncology Institute compare to Aveanna Healthcare?

Do institutionals & insiders believe in TOI or AVAH?

Do analysts rate TOI or AVAH?

Which has better earnings and valuation, TOI or AVAH?

Does the media prefer TOI or AVAH?

Is TOI or AVAH more profitable?

Which has more risk and volatility, TOI or AVAH?

Summary

How does Oncology Institute compare to Addus HomeCare?

Which has more volatility and risk, TOI or ADUS?

Does the media prefer TOI or ADUS?

Do analysts recommend TOI or ADUS?

Do insiders and institutionals believe in TOI or ADUS?

Is TOI or ADUS more profitable?

Which has higher earnings and valuation, TOI or ADUS?

Summary

How does Oncology Institute compare to Agilon Health?

Does the media refer more to TOI or AGL?

Which has more risk & volatility, TOI or AGL?

Which has stronger valuation and earnings, TOI or AGL?

Do insiders & institutionals have more ownership in TOI or AGL?

Is TOI or AGL more profitable?

Do analysts prefer TOI or AGL?

Summary

How does Oncology Institute compare to CareDx?

Which has more volatility and risk, CDNA or TOI?

Do analysts rate CDNA or TOI?

Which has better valuation and earnings, CDNA or TOI?

Is CDNA or TOI more profitable?

Do insiders & institutionals hold more shares of CDNA or TOI?

Does the media favor CDNA or TOI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TOI vs. The Competition

Oncology Institute Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools